Phaseline

Companies › Pheast Therapeutics

Pheast Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PHST001
anti-CD24 macrophage checkpoint inhibitor
CD24Phase 1Advanced Solid TumorsApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06840886PHST001Phase 1Advanced Solid TumorsOncologyApr 2029

Targets

CD24 (1)

Companies with the same targets

OncoC4

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.